Related Experiment Video
Updated: Jun 8, 2026
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
PLX4032: does it keep its promise for metastatic melanoma treatment?
Elisabeth Livingstone1, Lisa Zimmer, Sarah Piel
1University Hospital Essen, Department of Dermatology, Hufelandstr 55, 45122 Essen, Germany.
Importance Of The Field:
Activating mutations in the BRAF kinase gene have been identified in 50% of all melanomas. PLX4032, a selective and potent inhibitor of BRAF V600E mutant tumor cells, has shown inhibition of tumor growth in cell lines harboring BRAF V600E mutations. Data from early clinical trials showed promising results in the treatment of patients with metastatic melanoma.
Areas Covered In This Review:
An extensive literature search was conducted that included published articles and abstracts on PLX4032 to evaluate the existing data in both preclinical and Phase I-II studies.
What The Reader Will Gain:
The review comprises the rationale for choosing a selective BRAF inhibitor for certain types of melanoma, its mode of action, associated toxicities and potential pitfalls.
Take Home Message:
Despite the convincing response rates in Phase I trials, duration of tumor response is limited in some patients, and a cure cannot be expected. Intrinsic and acquired PLX4032 resistance still has to be investigated; signaling pathway switching is probably the most important factor for development of resistance. Combination therapy with simultaneous inhibition of different pathways might be more effective and warrants further investigation. The toxicity profile of PLX4032 is considerably low, and special attention is needed to address the development of keratoacanthomas and cutaneous squamous cell carcinomas.
Insights
PLX4032 shows promise for BRAF V600E melanoma but resistance limits duration. Further research into combination therapies and resistance mechanisms is crucial for improved outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Activating BRAF kinase gene mutations occur in 50% of melanomas.
- PLX4032 is a selective inhibitor targeting BRAF V600E mutations.
- Early clinical trials indicate promising results for metastatic melanoma treatment.
Purpose of the Study:
- Review the rationale for BRAF inhibitors in melanoma.
- Evaluate PLX4032's mechanism of action, efficacy, and safety.
- Summarize preclinical and Phase I-II clinical data.
Main Methods:
- Conducted an extensive literature search.
- Included published articles and abstracts on PLX4032.
- Focused on preclinical and Phase I-II studies.
Main Results:
- Discusses the rationale for selective BRAF inhibition.
- Details PLX4032's mode of action and associated toxicities.
- Highlights potential pitfalls and limitations.
Conclusions:
- Response rates are promising but duration is limited; a cure is not yet expected.
- Investigate intrinsic and acquired resistance, likely involving pathway switching.
- Combination therapy may improve efficacy; low toxicity profile noted, but monitor skin adverse events.
